Pharma Sector

The company attributed the decline primarily to lower lenalidomide sales in North America. The base business, excluding lenalidomide in North America, continued to deliver double-digit growth

The three-member committee will assess the effectiveness of the UCPMP, examine enforcement mechanisms and recommend measures to curb unethical pharmaceutical marketing practices

Torrent Pharma's Q2FY27 net profit declined 9.6 per cent to ₹534 crore despite a 50.8 per cent rise in revenue, as higher finance costs and depreciation weighed on earnings

The addressable ​market could grow at an annual rate of 15% through 2035, JP Morgan ‌analysts led by Yang Huang said in a note on Friday, given the countries' large diabetes and obesity burdens

Next phase of growth hinges on biologics, peptides, and drug-device combinations, say industry executives

Sun Pharma has accepted bids worth ₹7,816 crore for two bond tranches maturing in five years and one day, offering annual coupons of 8.05% and 8.20%, merchant bankers said.

Weak demand, AI-led growth concerns and US export headwinds weigh on defensive stocks, while valuation moderation signals potential opportunities

Generic brands now account for about 74% of monthly units as lower-priced products expand access, while doctors say the initial rush around the drug is cooling

The Supreme Court has directed the Centre to constitute a committee to examine statutory regulations on pharmaceutical marketing, including gifts and incentives offered to doctors

Specified speciality drugs from India and 19 other jurisdictions qualify for zero duty as the US extends its 100% pharma tariff to more companies; generics remain outside its scope

Pharmaceutical company MSD on Monday said it has appointed Vidhya Sundaram as Associate Vice President, Global Technology Centers, and Hyderabad Tech Center Lead. Vidhya, based in Hyderabad, will oversee MSD's global Technology Center strategy, working closely with global technology leaders to deepen collaboration across locations and support business outcomes, a company statement said. She will also lead the Hyderabad Tech Center, helping advance the digital capabilities that support MSD's work to deliver innovative solutions for human and animal health around the world. MSD, which operates as Merck & Co., Inc in the US and Canada markets, recently inaugurated the Tech Centre's expanded workplace in Hyderabad. Vidhya brings more than 20 years of experience building and scaling global capability organisations and driving business outcomes through digital and technology across the life sciences industry, the company said. Prior to joining MSD, Vidhya held leadership roles at Eli ...

AI is a utility for pharma companies, delivering drug discovery in a shorter time frame with far higher chances of success.

Among the broader indices, Sachin Gupta of Choice Broking expects Nifty Smallcap to outperform, based on the current chart setup. Among sectors, he sees relative strength in pharma and healthcare.

Respiratory launches, CDMO expansion and strong US and European businesses are key growth drivers; the stock trades at just under 16 times estimated FY28 earnings

Pharmarack data show anti-bacterial unit sales falling since 2023; experts say lower volumes alone do not indicate more appropriate antibiotic use

Natco Pharma on Tuesday said it is investing USD 14 million (over Rs 130 crore) in eGenesis Inc, a US-based biotechnology firm, through its two subsidiaries. As part of the transaction, Natco Pharma (Canada) Inc will invest USD 9.5 million and Natco Pharma South Africa Proprietary Ltd USD 4.5 million in eGenesis through convertible promissory notes, the Hyderabad-based company said in a regulatory filing. eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage and transform the treatment of organ failure, it added. In 2024, Natco Pharma had invested USD 8 million in eGenesis, Inc through preferred stock. The total investment made by it in eGenesis, Inc now stands at USD 22 million, the company said. The eGenesis Genome Engineering and Production (EGEN) platform is the only technology of its kind to comprehensively address cross-species molecular incompatibilities and viral risk via ..

Trump's pledge to apply 100% levy on firms making off-patent medications by 2028 (rising to 200% a year later) unless they move production to US faces formidable commercial and political obstacles

The product has been launched in 1,000 mg/10 mL and 5,000 mg/50 mL single-dose vials, along with a 10,000 mg/100 mL pharmacy bulk package

Govt's decision under the ₹10,000 cr Biopharma SHAKTI programme to create a dedicated scientific review cadre within CDSCO is an important reform

The successful closure of the inspection further strengthens Strides' regulatory track record and reinforces the company's commitment to supplying high-quality pharma products to patients across globe